ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Responds To IOM Report On Women’s Health Initiative

November 12, 1993

Children, Parents Differ In Decisionmaking On Cancer Treatment, Survivor Study Finds

July 29, 2005

Prostatectomy Lowers Death Risk Compared to Watchful Waiting

April 29, 2011

House Committee Investigates ESA Safety, Urges Amgen, J&J, To Stop Promotions.

March 23, 2007

Four Win 1988 General Motors Cancer Prizes

June 17, 1988

Patient Care Emerges as Major Concern Following Sequestration Cuts to Medicare

April 5, 2013